Myasthenia Gravis Treatment: 5 Things to Know - Medscape
Jun 28, 2024 · Myasthenia gravis, a rare autoimmune disease, can have devastating consequences. Stay current on the latest and emerging MG treatments with these five things …
AAN 2025: Key Highlights of Advances in Myasthenia Gravis
Apr 15, 2025 · Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including improved diagnostics and emerging therapies.
First-in-Class B-Cell Depleting Agent Promising for Myasthenia …
Oct 17, 2024 · A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with generalized myasthenia gravis.
Early Detection of MG May Lessen Symptom Severity - Medscape
Jul 12, 2024 · Early detection of myasthenia gravis, along with timely treatment, could mitigate symptom severity and optimize outcomes, reports Dr Nicholas Silvestri.
AAN 2025: Anticipating New Approaches in Myasthenia Gravis
Mar 25, 2025 · Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.
AAN 2025: Advancing Personalized Care in Myasthenia Gravis
Apr 28, 2025 · Nicholas J. Silvestri, MD, recounts how the 2025 American Academy of Neurology meeting was an exciting and energizing event, particularly in the realm of myasthenia gravis …
Myasthenia Gravis: Which Test Is Best? When and Why?
Jun 22, 2023 · Drs Nicholas Silvestri and Carolina Barnett-Tapia discuss what you need to know about immunopathogenesis and diagnosis for this relatively rare condition.
US Incidence, Prevalence of Myasthenia Gravis Rising - Medscape
May 2, 2023 · The incidence and prevalence of myasthenia gravis have increased in the United States, likely due to increased diagnosis and more awareness of the disease over time.
EMA Backs First FcRn Inhibitor for Myasthenia Gravis - Medscape
Sep 22, 2025 · In clinical trials, Imaavy plus standard therapy improved muscle strength and daily function in adults and adolescents with generalized myasthenia gravis.
Inebilizumab Effective Up to 52 Weeks in Myasthenia Gravis
Apr 10, 2025 · Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.